Boston Scientific Corporation (BSX)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Boston Scientific reads as neutral right now, with no clear lean either way.
- What's working
- Its price looks reasonable for what the business earns, compared with other healthcare companies.
- Worth watching
- Its price has been falling, trading below its recent averages.
Analyst price target
~12-month · 29 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular…
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 59,000
- Headquarters
- Marlborough, MA
Similar stocks
What’s behind the score
Valuation
P/E 18.0 — lower than 86% of Healthcare peers
P/B 2.6 — lower than 64% of Healthcare peers
P/S 3.1 — lower than 63% of Healthcare peers
EV/EBITDA 13.4 — lower than 60% of Healthcare peers
EV/Revenue 3.7 — lower than 63% of Healthcare peers
PEG 0.6 — lower than 85% of Healthcare peers
FCF yield 3.8% — higher than 55% of Healthcare peers
Profitability & quality
Gross margin 69.2% — higher than 67% of Healthcare peers
Operating margin 22.9% — higher than 50% of Healthcare peers
Net margin 17.5% — higher than 73% of Healthcare peers
ROE 15.3% — higher than 63% of Healthcare peers
ROA 6.2% — higher than 52% of Healthcare peers
Free cash flow is 67% of reported net income
Financial health
Debt/equity 0.5 — lower than 78% of Healthcare peers
Current ratio 1.24 — higher than 28% of Healthcare peers
Quick ratio 0.56 — higher than 14% of Healthcare peers
Cash/debt 0.04 — higher than 10% of Healthcare peers
Debt/EBITDA 2.21 — lower than 59% of Healthcare peers
Growth
Revenue growth 7.5% YoY — higher than 47% of Healthcare peers
Earnings growth 15.1% YoY — higher than 46% of Healthcare peers
Ownership & investor activity
Payout ratio 0.0% — somewhat unusual vs Healthcare peers
Institutions net sold, -13.4% of shares held
Insiders hold 0.3% of shares outstanding
2.9% of float sold short
Momentum
Below its 50- & 200-day averages
5% of the way from its 52-week low to high